Unlock instant, AI-driven research and patent intelligence for your innovation.
A method for establishing a nomogram model for predicting the curative effect of tumor immunotherapy
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for immunotherapy and establishment of methods, applied in the field of biomedicine, can solve the problem of unknown prognostic effect of important mutant genes, achieve good survival benefits, reduce errors in judgment, and be easy to popularize and apply.
Active Publication Date: 2022-02-25
SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
View PDF6 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, the important mutated genes associated with bTMB and their prognostic role in patients undergoing immunotherapy are largely unknown
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0039] 1137 patients with NSCLC receiving advanced second-line or third-line therapy (full cohort), including 289 patients (POPLAR cohort) from the POPLAR phase II trial (NCT01903993) and 850 patients (OAK cohort) from the OAK phase III trial (NCT02008227) , according to the PRISMA-IPD and TRIPOD guidelines, patients were randomly assigned to atezolizumab group (POPLAR, N=144; OAK, N=425) and docetaxel group (POPLAR, N=143; OAK, N =425).
[0040] (1) Mutationgene screening for hematological tumors
[0041] The blood of all test patients was drawn, and the genetic status was detected by FDA-approved FoundationOneCDx NGS. In the whole cohort of patients, TP53 (50%), LRP1B (31%), DNMT3A (23%), SPTA1 (18%), FAT3 (18%), KEAP1 (14%), NF1 (13%), MLL2 (12%), STAG2 (12%), FAT1 (11%), TSC1 (11%), MLL3 (10%), SMARCA4 (9%) %), EPHA6 (9%), PTPRD (9%), KRAS (9%), TET...
Embodiment 2
[0055] Verification and comparison of the model of embodiment 2
[0057] The OAK cohort (HR=0.37, 95% CI: 0.28-0.49, P Figure 6 A), POPLAR cohort (HR=0.37, 95% CI: 0.18-0.66, P Figure 6 B) and the whole cohort (HR=0.42, 95% CI: 0.33-0.54, P Figure 6 C) Patients are divided into high-risk group and low-risk group.
[0059] ROC curve analysis showed that the Nomogram A model predicted the 1-year, 2-year and 3-year OS of patients in the atezolizumab group better than the OAK cohort (AUC=0.694, 0.721, 0.733), POPLAR cohort (AUC=0.693, 0.726 , 0.711) and the whole cohort (AUC=0.684, 0.696, 0.714) all had good prediction performance. Using DCA curve analysis found (such as Figure 7 A), Nomogram A...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a nomogram model for predicting the curative effect of tumor immunotherapy and its establishment method. The invention obtains the factors significantly related to immunotherapy by analyzing and screening the mutationgene and clinical characteristic data of patients, and further constructs the corresponding The nomogram model; the present invention provides 3 kinds of nomogram models, which are suitable for different non-small celllungcancer patients, and assist in judging whether different patients can continue to receive treatment or choose to change the dressing; the model of the present invention is simple, intuitive, and easy to popularize and apply , can effectively help clinicians to accurately and individually evaluate atezolizumabimmunotherapy for patients with non-small celllungcancer when they receive immunotherapy and start treatment, so as to bring better survival benefits to patients. For non-small celllungcancer patients The effective application of immunotherapy for small celllung cancer is of great value.
Description
technical field [0001] The invention belongs to the field of biomedicine, and relates to a nomogram model for predicting curative effect of tumor immunotherapy and a method for establishing the same. Background technique [0002] According to statistics, lung cancer is the tumor with the highest cancer incidence and mortality rate in China, and 75%-85% of them are non-small celllung cancer (NSCLC). With the rapid development of immunotherapy, immune checkpoint inhibitors, especially programmed death-1 (PD-1) / programmed death-ligand-1 (PD-L1) inhibitors, have been used in the treatment of non-small cell lung cancer. A breakthrough has been made in China, which has changed the pattern of non-small cell lung cancer treatment. As a new hope for the treatment of tumors, immunotherapy has increased the 5-year survival rate of advanced non-small cell lung cancer several times. However, only 15%-20% of patients in the unselected population can benefit from it, and some patients w...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
